Lv1
30 积分 2024-04-25 加入
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
2天前
已完结
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
2个月前
已完结
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
2个月前
已完结
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
2个月前
已完结
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
2个月前
已完结
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
2个月前
已完结
P684: A MULTICENTER RETROSPECTIVE STUDY IN CHINA: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH CML-CP TREATED WITH DIFFERENT TYROSINE KINASE INHIBITORS
3个月前
已完结
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R‐IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high‐dose methotrexate‐based chemotherapy
4个月前
已完结
Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole
4个月前
已完结
皖公网安备34019202002308
